JP6109195B2 - キナーゼ阻害剤として有用な複素環置換されたピリジル化合物 - Google Patents
キナーゼ阻害剤として有用な複素環置換されたピリジル化合物 Download PDFInfo
- Publication number
- JP6109195B2 JP6109195B2 JP2014552311A JP2014552311A JP6109195B2 JP 6109195 B2 JP6109195 B2 JP 6109195B2 JP 2014552311 A JP2014552311 A JP 2014552311A JP 2014552311 A JP2014552311 A JP 2014552311A JP 6109195 B2 JP6109195 B2 JP 6109195B2
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- solvent
- acn
- alkyl
- isopropylamino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- QQPGYGHGXMLXGQ-YGPZHTELSA-N CC(C)N[C@H](CCCl)C(CN)C=O Chemical compound CC(C)N[C@H](CCCl)C(CN)C=O QQPGYGHGXMLXGQ-YGPZHTELSA-N 0.000 description 1
- IGJNPPWOFDEPSD-UHFFFAOYSA-N CC(C)Nc(cc(Nc(cc1)ccc1C#N)nc1)c1-c1nnc(C(N2CCNCC2)=O)[s]1 Chemical compound CC(C)Nc(cc(Nc(cc1)ccc1C#N)nc1)c1-c1nnc(C(N2CCNCC2)=O)[s]1 IGJNPPWOFDEPSD-UHFFFAOYSA-N 0.000 description 1
- JSADXPHJQCCHLN-CYBMUJFWSA-N CC(C)Nc(cc(Nc1cc2n[s]nc2cc1)nc1)c1-c1nnc(C(N(CC2)C[C@@H]2O)=O)[s]1 Chemical compound CC(C)Nc(cc(Nc1cc2n[s]nc2cc1)nc1)c1-c1nnc(C(N(CC2)C[C@@H]2O)=O)[s]1 JSADXPHJQCCHLN-CYBMUJFWSA-N 0.000 description 1
- KZGYPFONPYMBIF-UHFFFAOYSA-N CC(C)Nc(cc(Nc1ccc2nc[s]c2c1)nc1)c1-c1cc([nH]nc2)c2cc1 Chemical compound CC(C)Nc(cc(Nc1ccc2nc[s]c2c1)nc1)c1-c1cc([nH]nc2)c2cc1 KZGYPFONPYMBIF-UHFFFAOYSA-N 0.000 description 1
- CKIAHGRDNIJUIU-UHFFFAOYSA-N CC(C)Nc(cc(Nc1ccc2nc[s]c2c1)nc1)c1-c1nc(C(N)=O)c[s]1 Chemical compound CC(C)Nc(cc(Nc1ccc2nc[s]c2c1)nc1)c1-c1nc(C(N)=O)c[s]1 CKIAHGRDNIJUIU-UHFFFAOYSA-N 0.000 description 1
- UNUSCOSCJACYLL-UHFFFAOYSA-N CC(C)Nc(cc(Nc1ccc2nc[s]c2c1)nc1)c1-c1nnc(C(N(CC2)CC2NS(C)(=O)=O)=O)[s]1 Chemical compound CC(C)Nc(cc(Nc1ccc2nc[s]c2c1)nc1)c1-c1nnc(C(N(CC2)CC2NS(C)(=O)=O)=O)[s]1 UNUSCOSCJACYLL-UHFFFAOYSA-N 0.000 description 1
- WJNWVEVSXCURNR-UHFFFAOYSA-N CC(C)Nc(cc(Nc1ccc2nc[s]c2c1)nc1)c1C#N Chemical compound CC(C)Nc(cc(Nc1ccc2nc[s]c2c1)nc1)c1C#N WJNWVEVSXCURNR-UHFFFAOYSA-N 0.000 description 1
- NKKINTJIRCYONP-UHFFFAOYSA-N CC(C)Nc(cc(Nc1ccc2nc[s]c2c1)nc1)c1C(N)=S Chemical compound CC(C)Nc(cc(Nc1ccc2nc[s]c2c1)nc1)c1C(N)=S NKKINTJIRCYONP-UHFFFAOYSA-N 0.000 description 1
- 0 CC(C)Nc(cc(nc1)Cl)c1-c1nnc(NCCC*)[o]1 Chemical compound CC(C)Nc(cc(nc1)Cl)c1-c1nnc(NCCC*)[o]1 0.000 description 1
- SXWQJSSKXJQKRM-UHFFFAOYSA-N CC(C)Nc1cc(Cl)ncc1-c1nc(C(N)=O)n[o]1 Chemical compound CC(C)Nc1cc(Cl)ncc1-c1nc(C(N)=O)n[o]1 SXWQJSSKXJQKRM-UHFFFAOYSA-N 0.000 description 1
- KXVDSEWWEHKHAD-UHFFFAOYSA-N CC(C)Nc1cc(Cl)ncc1C(NN)=O Chemical compound CC(C)Nc1cc(Cl)ncc1C(NN)=O KXVDSEWWEHKHAD-UHFFFAOYSA-N 0.000 description 1
- MPSVVZLIWUIPOL-UHFFFAOYSA-N CCOC(/C(/N)=N/N)=O Chemical compound CCOC(/C(/N)=N/N)=O MPSVVZLIWUIPOL-UHFFFAOYSA-N 0.000 description 1
- DMUYVIYISCGQSV-GOSISDBHSA-N CNC(c(cc1)ccc1Nc1cc(Nc(cc2)cc3c2nc[s]3)ncc1-c1nnc(C(N(CC2)C[C@@H]2O)=O)[s]1)=O Chemical compound CNC(c(cc1)ccc1Nc1cc(Nc(cc2)cc3c2nc[s]3)ncc1-c1nnc(C(N(CC2)C[C@@H]2O)=O)[s]1)=O DMUYVIYISCGQSV-GOSISDBHSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261586155P | 2012-01-13 | 2012-01-13 | |
| US61/586,155 | 2012-01-13 | ||
| PCT/US2013/021093 WO2013106612A1 (en) | 2012-01-13 | 2013-01-11 | Heterocyclic-substituted pyridyl compounds useful as kinase inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015503620A JP2015503620A (ja) | 2015-02-02 |
| JP2015503620A5 JP2015503620A5 (enExample) | 2016-02-12 |
| JP6109195B2 true JP6109195B2 (ja) | 2017-04-05 |
Family
ID=47595097
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014552311A Expired - Fee Related JP6109195B2 (ja) | 2012-01-13 | 2013-01-11 | キナーゼ阻害剤として有用な複素環置換されたピリジル化合物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US9242975B2 (enExample) |
| EP (1) | EP2802576B1 (enExample) |
| JP (1) | JP6109195B2 (enExample) |
| CN (1) | CN104159896B (enExample) |
| ES (1) | ES2686500T3 (enExample) |
| WO (1) | WO2013106612A1 (enExample) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014058685A1 (en) * | 2012-10-08 | 2014-04-17 | Merck Sharp & Dohme Corp. | Inhibitors of irak4 activity |
| MX2015005562A (es) | 2012-11-08 | 2015-07-23 | Squibb Bristol Myers Co | Compuestos de piridilo sustituidos con heteroarilo utiles como moduladores de cinasa. |
| WO2014074657A1 (en) | 2012-11-08 | 2014-05-15 | Bristol-Myers Squibb Company | Bicyclic heterocycle substituted pyridyl compounds useful as kinase modulators |
| GB201311891D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| GB201311888D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| TWI667233B (zh) | 2013-12-19 | 2019-08-01 | 德商拜耳製藥公司 | 新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途 |
| UY35935A (es) * | 2014-01-03 | 2015-06-30 | Bristol Myers Squibb Company Una Corporación Del Estado De Delaware | Compuestos de nicotinamida sustituida con heteroarilo como inhibidores de quinasa y moduladores de irak-4 |
| US20180228907A1 (en) | 2014-04-14 | 2018-08-16 | Arvinas, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| AR105114A1 (es) | 2015-06-24 | 2017-09-06 | Bristol Myers Squibb Co | Compuestos de aminopiridina sustituida con heteroarilo |
| AR105113A1 (es) * | 2015-06-24 | 2017-09-06 | Bristol Myers Squibb Co | Compuestos de aminopiridina sustituida con heteroarilo |
| TW201713655A (zh) | 2015-06-24 | 2017-04-16 | 必治妥美雅史谷比公司 | 經雜芳基取代之胺基吡啶化合物 |
| WO2018071794A1 (en) * | 2016-10-14 | 2018-04-19 | Nimbus Lakshmi, Inc. | Tyk2 inhibitors and uses thereof |
| JOP20180011A1 (ar) | 2017-02-16 | 2019-01-30 | Gilead Sciences Inc | مشتقات بيرولو [1، 2-b]بيريدازين |
| WO2018165338A2 (en) * | 2017-03-07 | 2018-09-13 | uBiome, Inc. | Therapeutic & diagnostics compositions targeting toll-like receptors and methods thereof |
| SMT202100568T1 (it) * | 2017-05-11 | 2021-11-12 | Bristol Myers Squibb Co | Tienopiridine e benzotiofeni utili come inibitori di irak4 |
| WO2019060693A1 (en) | 2017-09-22 | 2019-03-28 | Kymera Therapeutics, Inc. | CRBN LIGANDS AND USES THEREOF |
| AU2018338314B2 (en) | 2017-09-22 | 2024-12-12 | Kymera Therapeutics, Inc | Protein degraders and uses thereof |
| EP3710443A1 (en) | 2017-11-17 | 2020-09-23 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides |
| WO2019111218A1 (en) | 2017-12-08 | 2019-06-13 | Cadila Healthcare Limited | Novel heterocyclic compounds as irak4 inhibitors |
| BR112020012635A2 (pt) | 2017-12-22 | 2020-12-01 | Ravenna Pharmaceuticals, Inc. | derivados de aminopiridina como inibidores de fosfatidilinositol fosfato quinase |
| IL315310A (en) | 2017-12-26 | 2024-10-01 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| EP3737675A4 (en) | 2018-01-12 | 2022-01-05 | Kymera Therapeutics, Inc. | Crbn ligands and uses thereof |
| EP3737666A4 (en) | 2018-01-12 | 2022-01-05 | Kymera Therapeutics, Inc. | PROTEIN DEGRADATION AGENTS AND ASSOCIATED USES |
| WO2020010227A1 (en) | 2018-07-06 | 2020-01-09 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| EP3817748A4 (en) | 2018-07-06 | 2022-08-24 | Kymera Therapeutics, Inc. | TRICYCLIC CRBN LIGANDS AND USES THEREOF |
| TWI842978B (zh) | 2018-07-13 | 2024-05-21 | 美商基利科學股份有限公司 | 衍生物 |
| TWI727392B (zh) * | 2018-08-13 | 2021-05-11 | 美商基利科學股份有限公司 | 噻二唑irak4抑制劑 |
| WO2020106059A1 (ko) | 2018-11-21 | 2020-05-28 | 한국화학연구원 | Irak4 저해제로서 신규의 삼중고리 화합물 |
| KR102329235B1 (ko) | 2018-11-21 | 2021-11-22 | 한국화학연구원 | Irak4 저해제로서 신규의 삼중고리 화합물 |
| SG11202105424PA (en) | 2018-11-30 | 2021-06-29 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| TW202112767A (zh) | 2019-06-17 | 2021-04-01 | 美商佩特拉製藥公司 | 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物 |
| CN114127075B (zh) | 2019-07-18 | 2024-05-14 | 百时美施贵宝公司 | 可用作IRAK4抑制剂的吡唑并[3,4-d]吡咯并[1,2-b]哒嗪基化合物 |
| JP7570399B2 (ja) | 2019-07-18 | 2024-10-21 | ブリストル－マイヤーズ スクイブ カンパニー | Ｉｒａｋ４阻害剤として有用な三環式ヘテロアリール化合物 |
| CN114174304B (zh) | 2019-07-23 | 2024-05-17 | 百时美施贵宝公司 | 可用作irak4抑制剂的噻吩并吡啶基化合物和噻唑并吡啶基化合物 |
| JP7682154B2 (ja) | 2019-08-06 | 2025-05-23 | ブリストル－マイヤーズ スクイブ カンパニー | Ｉｒａｋ４阻害剤として有用な二環ヘテロ環式化合物 |
| WO2021127283A2 (en) | 2019-12-17 | 2021-06-24 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| JP2023509366A (ja) | 2019-12-17 | 2023-03-08 | カイメラ セラピューティクス， インコーポレイテッド | Ｉｒａｋ分解剤およびそれらの使用 |
| WO2021158495A1 (en) * | 2020-02-03 | 2021-08-12 | Bristol-Myers Squibb Company | Benzo[5,6][1,4]dioxino[2,3-b]pyridine compounds useful as irak4 inhibitors |
| ES2977339T3 (es) | 2020-02-03 | 2024-08-22 | Bristol Myers Squibb Co | Compuestos heteroarílicos tricíclicos útiles como inhibidores de IRAK4 |
| TW202210483A (zh) | 2020-06-03 | 2022-03-16 | 美商凱麥拉醫療公司 | Irak降解劑之結晶型 |
| MX2023007852A (es) | 2020-12-30 | 2023-07-07 | Kymera Therapeutics Inc | Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos. |
| WO2022174268A1 (en) | 2021-02-15 | 2022-08-18 | Kymera Therapeutics, Inc. | Irak4 degraders and uses thereof |
| AU2022271290A1 (en) | 2021-05-07 | 2023-11-23 | Kymera Therapeutics, Inc. | Cdk2 degraders and uses thereof |
| WO2023076556A1 (en) | 2021-10-29 | 2023-05-04 | Kymera Therapeutics, Inc. | Irak4 degraders and synthesis thereof |
| IL314437A (en) | 2022-01-31 | 2024-09-01 | Kymera Therapeutics Inc | IRAK joints and their uses |
| WO2026005537A1 (ko) * | 2024-06-28 | 2026-01-02 | 주식회사 대웅제약 | 신규한 화합물, 및 이를 포함하는 암 또는 자가 면역 질환의 예방 또는 치료용 약학적 조성물 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002102800A1 (en) | 2001-06-15 | 2002-12-27 | Vertex Pharmaceuticals Incorporated | 5-(2-aminopyrimidin-4-yl) benzisoxazoles as protein kinase inhibitors |
| AUPR688101A0 (en) | 2001-08-08 | 2001-08-30 | Luminis Pty Limited | Protein domains and their ligands |
| GB0211019D0 (en) | 2002-05-14 | 2002-06-26 | Syngenta Ltd | Novel compounds |
| JP4529685B2 (ja) | 2002-06-28 | 2010-08-25 | アステラス製薬株式会社 | ジアミノピリミジンカルボキサミド誘導体 |
| MXPA05007503A (es) * | 2003-01-17 | 2005-09-21 | Warner Lambert Co | Heterociclicos 2-aminopiridina sustituidos como inhibidores de proliferacion celular. |
| CN1820001A (zh) | 2003-07-10 | 2006-08-16 | 神经能质公司 | 经取代的杂环二芳基胺类似物 |
| GB0402653D0 (en) | 2004-02-06 | 2004-03-10 | Cyclacel Ltd | Compounds |
| US7521457B2 (en) | 2004-08-20 | 2009-04-21 | Boehringer Ingelheim International Gmbh | Pyrimidines as PLK inhibitors |
| FR2896503B1 (fr) | 2006-01-23 | 2012-07-13 | Aventis Pharma Sa | Nouveaux derives soufres d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases |
| EP2063962A2 (en) * | 2006-09-07 | 2009-06-03 | Biogen Idec MA Inc. | Irak modulators for treating an inflammatory condition, cell proliferative disorder, immune disorder |
| SG177221A1 (en) * | 2006-12-15 | 2012-01-30 | Abbott Lab | Novel oxadiazole compounds |
| US8273759B2 (en) | 2007-06-08 | 2012-09-25 | Bayer Cropscience Ag | Fungicide heterocyclyl-pyrimidinyl-amino derivatives |
| WO2009046416A1 (en) | 2007-10-05 | 2009-04-09 | Targegen Inc. | Anilinopyrimidines as jak kinase inhibitors |
| GB0719644D0 (en) * | 2007-10-05 | 2007-11-14 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| JP2012529535A (ja) | 2009-06-12 | 2012-11-22 | ブリストル−マイヤーズ スクイブ カンパニー | キナーゼモジュレーターとして有用なニコチンアミド化合物 |
| JP2012254939A (ja) * | 2009-10-07 | 2012-12-27 | Astellas Pharma Inc | オキサゾール化合物 |
| EP2493863B1 (en) | 2009-10-30 | 2015-02-25 | Janssen Pharmaceutica NV | Phenoxy-substituted pyrimidines as opioid receptor modulators |
| WO2011093501A1 (ja) | 2010-02-01 | 2011-08-04 | 日本ケミファ株式会社 | Ｇｐｒ１１９作動薬 |
| KR20140026532A (ko) | 2011-04-29 | 2014-03-05 | 이칸 스쿨 오브 메디슨 엣 마운트 시나이 | 키나제 억제제 |
| ES2575604T3 (es) | 2012-01-13 | 2016-06-29 | Bristol-Myers Squibb Company | Compuestos de piridilo sustituidos con tiazolilo o tiadiazolilo útiles como inhibidores cinasa |
| US8987311B2 (en) | 2012-01-13 | 2015-03-24 | Bristol-Myers Squibb Company | Triazolyl-substituted pyridyl compounds useful as kinase inhibitors |
-
2013
- 2013-01-11 ES ES13700828.0T patent/ES2686500T3/es active Active
- 2013-01-11 WO PCT/US2013/021093 patent/WO2013106612A1/en not_active Ceased
- 2013-01-11 CN CN201380013438.7A patent/CN104159896B/zh not_active Expired - Fee Related
- 2013-01-11 US US14/371,456 patent/US9242975B2/en active Active
- 2013-01-11 JP JP2014552311A patent/JP6109195B2/ja not_active Expired - Fee Related
- 2013-01-11 EP EP13700828.0A patent/EP2802576B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2013106612A1 (en) | 2013-07-18 |
| CN104159896B (zh) | 2017-05-24 |
| ES2686500T3 (es) | 2018-10-18 |
| EP2802576A1 (en) | 2014-11-19 |
| CN104159896A (zh) | 2014-11-19 |
| EP2802576B1 (en) | 2018-06-27 |
| US9242975B2 (en) | 2016-01-26 |
| US20150011532A1 (en) | 2015-01-08 |
| JP2015503620A (ja) | 2015-02-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6109195B2 (ja) | キナーゼ阻害剤として有用な複素環置換されたピリジル化合物 | |
| JP6096807B2 (ja) | キナーゼ阻害剤として有用なトリアゾリル置換されたピリジル化合物 | |
| JP6096219B2 (ja) | キナーゼ阻害剤として有用なトリアゾリルまたはトリアジアゾリル置換されたピリジル化合物 | |
| JP6215338B2 (ja) | キナーゼモジュレーターとして有用な二環式ヘテロ環置換ピリジル化合物 | |
| JP7097373B2 (ja) | キナーゼ阻害剤としてのアミノトリアゾロピリジン | |
| KR102759231B1 (ko) | 키나제 억제제로서의 아미노피롤로트리아진 | |
| US11440913B2 (en) | Aminoimidazopyridazines as kinase inhibitors | |
| JP7577655B2 (ja) | 環状尿素 | |
| AU2005236063A1 (en) | 2, 4, 6-substituted pyridyl derivative compounds useful as beta-secretase inhibitors for the treatment of Alzheimer's disease | |
| EP4463452B1 (en) | C-myc mrna translation modulators and uses thereof in the treatment of cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20151217 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20151217 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20160219 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20160707 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160719 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20161019 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161202 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170117 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170119 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20170207 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170307 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6109195 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |